Using exome or transcriptome data from more than 400 metastatic, castration-resistant prostate cancer cases, researchers identified survival-related alterations in the RB1 gene.
The group plans to use the assay for translational studies on metastasis and drug resistance initially and to develop a clinical version later on.
Exome sequencing on tumors from metastatic, castration-resistant prostate cancer cases responding to immunotherapy led to homologous recombination defects.
Researchers analyzed HERBY trial data to uncover a subgroup of patients with MAPK pathway alterations who had increased overall survival.
Many molecularly distinct subgroups emerged from a meta-analysis bringing together more than 1,000 high-grade glioma or diffuse intrinsic pontine glioma cases.
Results of a new study offer preliminary evidence that blood tests could select patients for treatment, and track response and resistance.